Valneva's 15min chart shows KDJ Death Cross, Bearish Marubozu formation.

Valneva's 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu at 10/09/2025 15:00. This suggests that the momentum of the stock price is shifting towards the downside, potentially leading to further decreases in value. Sellers currently dominate the market, and it is likely that this bearish momentum will continue.

Valneva SE's stock experienced a significant decline on September 10, 2025, following the company's announcement of a delay in the release of Phase 3 Lyme disease vaccine data and a reduction in its 2025 financial guidance. The company's shares fell by 7% in response to the news, triggering a KDJ Death Cross and a Bearish Marubozu on the 15-minute chart, indicating a shift in the stock's momentum towards the downside Valneva falls after Lyme disease vaccine data delay, outlook cut^[1].

The delay in the Phase 3 data release, which was previously expected in late 2025, has now been pushed back to the first half of 2026. Additionally, Valneva has cut its annual revenue forecast for 2025 to a range of €165-180 million, down from the previously projected €180-190 million. Research and development (R&D) investments have also been reduced to €80-90 million from the earlier forecast of €90-100 million Valneva falls after Lyme disease vaccine data delay, outlook cut^[1].

The company's stock further declined after the U.S. Food and Drug Administration (FDA) suspended the product license for its IXCHIQ vaccine. Valneva's new financial guidance, following the FDA's suspension, projects product sales between €155-170 million and total revenues of €165-180 million, a significant reduction from the previous estimates of €170-180 million and €180-190 million, respectively. R&D investments have been further cut to €80-90 million Valneva stock falls after FDA suspension forces guidance cut^[2].

Valneva has secured a debt facility for up to $500 million with Pharmakon Advisors, LP, which will extend its debt repayment timeline from Q1 2026 to Q4 2030. The company's commercial business is still expected to be cash flow positive despite the guidance reduction Valneva stock falls after FDA suspension forces guidance cut^[2].

The Phase 3 clinical trial of Valneva's Lyme disease vaccine candidate, being developed with Pfizer (NYSE:PFE), remains on track. The companies still aim to submit regulatory applications in 2026, with a potential launch in the second half of 2027 pending approval Valneva stock falls after FDA suspension forces guidance cut^[2].